Cognoptix has created a noninvasive eye-scanning device, called SAPPHIRE II, that uses a specific beta amyloid signature in the eye to determine whether a patient is at risk for Alzheimer's disease. The Acton, Mass.-based company will release information on the device Wednesday at a conference in Boston.
Eye-scanning device is designed to detect Alzheimer's disease
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||